In recent years, multiple targeted drugs have also been approved by FDA for the treatment of BC, including inhibitors of cyclin-dependent kinase 4/6 (CDK4/6), mTOR, poly (ADP-ribose) polymerase (PARP), and epithelial growth factor receptor (EGFR) [46]. This evidence concerns the gene CDK4 and breast cancer.